IBB241018C144500
- 2.16
- 0.000.00%
iShares Biotechnology ETF Newsroom
Larimar Therapeutics' New Drug Could Transform Treatment For Rare Neurological Disease, Analyst Sees Over 200% Upside For Stock
Alnylam Pharmaceuticals Analyst Ratings
Regeneron Pharmaceuticals Analyst Ratings
Here's How Much $1000 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth Today
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday as Big Banks Gather Investors' Confidence
Argenx Highlights Patient Impact Data Across Immunology Programs At 2024 AANEM And MGFA Scientific Session
Trump or Harris? Analysts are hotly debating the impact of the election results on various sectors of the US stock market.
①Over the past 8 years, the Trump administration and the Biden-Harris administration have fully demonstrated their policy orientations; ②Overall, industries such as finance and technology that are under the focus of regulation by the Biden administration are more likely to benefit from the rollback policies of the Trump administration, while the bullish impact on other industries is relatively less pronounced.
Jasper Gains 11% on Data for Briquilimab in Urticaria
Vertex Pharmaceuticals Analyst Ratings
Morgan Stanley Screens for Quality Cyclicals as Economic Surprises, Yields Back Upgrade
Eight Stocks Positioned for Short Sales – Oppenheimer Asset Management
Amgen Analyst Ratings
After eight weeks of selling off, the hedge fund bought back US stocks, achieving the fastest speed since 2021.
The US stock market is currently experiencing active buying and market growth, but the market's high valuation is a concerning issue that may trigger future adjustments.
The bull market in US stocks will enter its third year. The three major futures are mixed before the market. | Focus tonight.
nasdaq 100 index futures rose more than 0.4% in pre-market trading; Apple is set to launch a $2000 Vision headset as early as next year; Taiwan Semiconductor plans to establish more chip factories in europe; Glaxosmithkline's experimental drug for treating rhinitis showed positive results in clinical trials.
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Monday Ahead of Earnings Deluge
Amgen Downgraded at Truist on MariTide Prospects for Obesity
Eli Lilly CEO Told UK Health Secretary Its Alzheimer's Treatment Could "Prevent" Disease: FT
Weight Loss Drugs Have One Big Issue; These Companies Want to Fix It
Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names
Cantor Fitzgerald Reiterates Neutral on Alnylam Pharmaceuticals, Maintains $220 Price Target